Glucagon Receptor Antagonist LGD-6972 Significantly Lowers HbA1c and Is Well Tolerated after 12-Week Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 73-OR ◽  
Author(s):  
JEREMY PETTUS ◽  
ERIC G. VAJDA ◽  
JAMES PIPKIN ◽  
GRETCHEN WILLIAMSON ◽  
MIRIAM A. ZANGMEISTER ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Receptor Antagonist ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist

Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus

2016 ◽  
Vol 18 (8) ◽  
pp. 795-802 ◽  
Author(s):  
D. J. Kazierad ◽  
A. Bergman ◽  
B. Tan ◽  
D. M. Erion ◽  
V. Somayaji ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Receptor Antagonist ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist

scholarly journals Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

2017 ◽  
Vol 19 (11) ◽  
pp. 1521-1528 ◽  
Author(s):  
Cristina B. Guzman ◽  
Xiaotian M. Zhang ◽  
Rong Liu ◽  
Arie Regev ◽  
Sudha Shankar ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Liver Fat ◽  
Glucagon Receptor ◽  
Glucagon Receptor Antagonist

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial

Endocrine ◽  
2018 ◽  
Vol 62 (2) ◽  
pp. 371-380 ◽  
Author(s):  
Barry Gumbiner ◽  
Brooke Esteves ◽  
Vanessa Dell ◽  
Tenshang Joh ◽  
Pamela D. Garzone ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Antagonist ◽  
Controlled Trial ◽  
Phase 1 ◽  
Double Blind ◽  
Glucagon Receptor ◽  
Double Blind Placebo ◽  
Dose Study ◽  
Glucagon Receptor Antagonist
Sign in / Sign up

Export Citation Format

Share Document